Application of Caerin 1.1/1.9 combined with anti-CD47 antibody in preparing drug for treating melanoma

Abstract

The present invention belongs to the field of biotechnology, and particularly relates to an application of Caerin 1.1/1.9 combined with an anti-CD47 antibody in preparing a drug for treating melanoma. In the present invention, an amino acid sequence of the Caerin 1.1 is shown in SEQ ID NO.1; and an amino acid sequence of the Caerin 1.9 is shown in SEQ ID NO.2. The Caerin 1.1/1.9 of the present invention may promote B16 cells to highly express CD47 while leading to apoptosis of the B16 cells, promote macrophages to phagocytose tumor cells in the presence of anti-CD47 antibodies, improve the curative effect of the Caerin 1.1/1.9, which is also superior to that of a single anti-CD47 antibody, and lays a foundation for expanding the application of CD47 inhibition/blocking drugs.

Dependencies are inferred from the claim text.